Irinotecan Hydrochloride Injection, Solution
Product Images NDC 45963-614

6 FDA label images from Actavis Pharma, Inc. · Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 6 technical images submitted to the FDA as part of the official labeling for Irinotecan Hydrochloride (NDC 45963-614). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Actavis Pharma, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

9a178e71-figure-01 (Image 1)

9a178e71-figure-01 (Image 1)
Chemical structure of Irinotecan Hydrochloride, showing the molecular arrangement with indicated hydrochloride (HCl) and tri-hydrate (3 H2O) components.*
FDA Label Image

New (Image 2)

New (Image 2)
A Kaplan-Meier survival curve graph comparing the probability of survival over months between two treatment groups: Irinotecan/5-FU/LV and 5-FU/LV alone. The x-axis represents time in months, and the y-axis shows survival probability, with a statistical significance indicated by p<0.05 using a log-rank test.*
FDA Label Image

New (Image 3)

New (Image 3)
A Kaplan-Meier survival probability curve comparing two treatment groups over a 30-month period. The vertical axis shows probability, and the horizontal axis shows time in months. The graph features two labeled survival curves: one for Irinotecan/5-FU/LV and one for 5-FU/LV, indicating different survival probabilities over time with a statistical significance marked (p < 0.05, log-rank test).*
FDA Label Image

9a178e71-figure-02 (Image 4)

9a178e71-figure-02 (Image 4)
A survival probability Kaplan-Meier curve comparing Irinotecan treatment versus Best Supportive Care (BSC) over months. The y-axis shows survival probability from 0.0 to 1.0, and the x-axis shows time in months up to 21. The graph includes median follow-up and survival times for both groups with noted statistical significance (p=0.0001).*
FDA Label Image

9a178e71-figure-03 (Image 5)

9a178e71-figure-03 (Image 5)
A line graph comparing the probability of survival over time in months between Irinotecan and 5-FU treatments. The graph includes data on the number of subjects, median follow-up duration, median survival months, and a p-value from a log-rank test indicating statistical significance.*
FDA Label Image

New (Image 6)

New (Image 6)
Packaging label for Irinotecan Hydrochloride Injection, USP, 40 mg/2 mL (20 mg/mL as the trihydrate), a single-dose vial. Label shows manufacturer as Teva Pharmaceuticals and indicates the product must be diluted and used intravenously. Warnings note it is a cytotoxic agent. Storage and usage instructions are included, along with NDC 45963-614-51 and barcodes.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.